NEW YORK (GenomeWeb News) – Galapagos, the Belgian drug development and drug screening services firm, has raised €18.2 million ($27.1 million) through the placement of 2,125,925 new ordinary shares at a price of €8.55 per share.

The shares are being placed with unnamed international institutional investors. Delivery of the shares is expected to take place on Oct. 21.

Galapagos plans to use the funds to support clinical development of drug candidates, including a phase II study of a rheumatoid arthritis drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.